RT Journal Article
ID 2330940469780448
A1 Dominguez, Donye
A1 Zhang, Yi
A1 Zhang, Bin
T1 IL-33 in Tumor Immunity: Nothing to Sneeze At
JF Critical Reviews™ in Immunology
JO CRI
YR 2018
FD 2018-11-29
VO 38
IS 6
SP 453
OP 470
K1 IL-33
K1 ST2
K1 CD8+ T cells
K1 dendritic cells
K1 antitumor immunity
AB Although immunotherapy has been at the forefront of cancer therapy for the last several years, better
clinical responses are still desired. Interleukin-33 is perhaps one of the most overlooked antitumor cytokines. Its
ability to promote type 1 immune responses, which control tumor growth in preclinical animal models is overshadowed
by its association with type 2 immunity and poor prognosis in some human cancers. Accumulating evidence
shows that IL-33 is a powerful new tool for restoring and enhancing the body's natural antitumor immunity cycle.
Furthermore, the antitumor mechanisms of IL-33 are two-fold, as it can directly boost CD8+ T cell function and restore dendritic cell dysfunction in vivo. Mechanistic studies have identified a novel pathway induced by IL-33 and its receptor ST2 in which dendritic cells avoid dysfunction and retain cross-priming abilities in tumor-bearing conditions. Here, we also comment on IL-33 data in human cancers and explore the idea that endogenous IL-33 may not deserve its reputation for promoting tumor growth. In fact, tumors may hijack the IL-33/ST2 axis to avoid immune surveillance and escape antitumor immunity.
PB Begell House
LK https://www.dl.begellhouse.com/journals/2ff21abf44b19838,50bd6b32256cb3e1,2330940469780448.html